Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

**Figure S1.** PRISMA Flow Diagram, Large B-Cell Lymphoma (LBCL)

*PICOS - population, intervention, comparator, outcomes, and study design*
**Figure S2.** MAIC of experimental CAR T-cells and Yescarta regarding PFS among patients who received infusion. Kaplan Meier survival curves. Hazard Ratios and 95% Confidence Intervals computed through Cox Proportional Hazards Models.

A. Dual targeting

**Tandem CD19. CD20 with 4-1BBζ**

Co-infusion CD19 & CD20 with 4-1BBζ

B. Third generation CARs

**CD19 with CD28ζ & 4-1BBζ**

C. Sequential administration of ASCT and CD19.CD28ζ
D. Modified co-stimulatory domain for reduced toxicity:

Hu19.CD8.28Z

CD19. BBz.86

E. Alternative target antigen

CD20. 4-1BBζ

F. Alternative co-stimulatory domain

CD19. 4-1BBζ